The clinical entities of IPEX and APS1 caused by the mutations of FOXP3 and AIRE, respectively, are likely to be the first of a string of new primary monogenic diseases that can be used for discovery of immune regulatory mechanisms and targeted interventions. This evidence concerns the gene AIRE and autoimmune polyendocrine syndrome type 1.